Exhibit 10.10

2007 COMPENSATION INFORMATION FOR EXECUTIVE OFFICERS

The table below provides certain information
regarding (i) the annual base salaries as of January 1, 2007 (except as noted) of the current and former executive officers of Kosan Biosciences Incorporated (the Company) listed below; (ii) the cash bonuses awarded to the
current and former executive officers of the Company listed below under the Companys 2007 Executive Officer Cash Bonus Plan (the Bonus Plan); and (iii) the number of shares of the Companys common stock subject to stock
options granted in January 2007 (except as noted) to the current and former executive officers of the Company listed below:



|                                                                                             |  |                           |  |                    |  |                                            
|-------------------------------------------------------------------------------------------- |  | ------------------------- |  | ------------------ |  | -------------------------------------------
|Executive Officer                                                                            |  | 2007 AnnualBase Salary($) |  | Cash BonusAward($) |  | Number ofShares Subjectto StockOptions (#)5
|                                                                                             |  |                           | 
|Gary S. Titus, C.P.A.                                                                        |  | 312,000                   |  | 99,782             |  | 15,000                                     
|Senior Vice President and Chief Financial Officer                                            |  |                           |  |                    |  |                                            
|                                                                                             |  |                           | 
|Pieter J. Licari                                                                             |  | 254,000                   |  | 73,438             |  | 37,500                                     
|Senior Vice President, Manufacturing and Operations                                          |  |                           |  |                    |  |                                            
|                                                                                             |  |                           | 
|Pieter B.M.W.M. Timmermans                                                                   |  | 260,000                   |  | 71,273             |  | 37,500                                     
|Senior Vice President, Drug Discovery and Preclinical Development                            |  |                           |  |                    |  |                                            
|                                                                                             |  |                           | 
|Jonathan Wright1                                                                             |  | 280,000                   |  |                   |  | 140,000                                    
|Senior Vice President, General Counsel and Secretary                                         |  |                           |  |                    |  |                                            
|Robert G. Johnson, Jr.2                                                                      |  | 416,000                   |  | 165,672            |  | 100,000                                    
|Former President and Chief Executive Officer                                                 |  |                           |  |                    |  |                                            
|                                                                                             |  |                           | 
|Margaret A. Horn3                                                                            |  | 312,000                   |  |                   |  | 45,000                                     
|Former Senior Vice President, Legal and Corporate Development, General Counsel and Secretary |  |                           |  |                    |  |                                            
|                                                                                             |  |                           | 
|Robert De Jager4                                                                             |  | 326,000                   |  |                   |  |                                           
|Former Senior Vice President, Clinical Development and Chief Medical Officer                 |  |                           |  |                    |  |                                            



|1 | Mr. Wright was appointed as the Companys Senior Vice President, General Counsel and Secretary effective
December 4, 2007. Mr. Wright was not a participant in the Companys 2007 Executive Officer Cash Bonus Plan. The option granted to Mr. Wright as shown in the table above was granted in November 2007.
|- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|2 | Dr. Johnson resigned as the Companys President and Chief Executive Officer effective February 27, 2008.
|- | --------------------------------------------------------------------------------------------------------



|3 | Ms. Horn resigned as the Companys Senior Vice President, Legal and Corporate Development, General Counsel and
Secretary effective August 24, 2007.
|- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|4 | Dr. De Jager resigned as the Companys Senior Vice President, Clinical Development and Chief Medical Officer
effective August 8, 2007.
|- | --------------------------------------------------------------------------------------------------------------------------------------



|5 | Stock options vest over a period of four years subject to continuous service and were granted with an exercise price
equal to the fair market value on the date of grant (as determined in accordance with the Companys 2006 Equity Incentive Plan).
|- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------